Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Keith Feral who wrote (362)	12/11/2007 9:19:27 PM
From: buffalodon2003	Respond to of 370

Based upon my understanding of past events and interpretation, I believe they intend to present an application with the phase II results since cloretazine (single agent) has been involved in phase III testing (with ARA-C). I am not sure which part is the head versus the tail. I believe they will be trying to separate the toxidity of ARA-C from their Cloretazine in Phase III with the favorable end point accomplishments in Phase II. You logically seem correct. Normally, there would be a phase III (single agent). The believe seems to be that phase III may not matter as much due to significant test results of phase II. I thought yesterdays price movement (up to 1.10 and then down) was very logical (profit taking in 1st hour). I am a little bewildered by todays movement. I felt that good volume would exist, but a modest breakeven to .03 up. I did not understand the .11 drop. Again, I still believe a good buy opportunity exists, because a number of positive PR events exist before FDA decision (crap shoot). Some good money to be made (i.e. 25% short term gain). Comments.